Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
11:16am, Thursday, 28'th May 2026
Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
08:00am, Wednesday, 27'th May 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
10:55am, Tuesday, 19'th May 2026
The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
12:51pm, Friday, 15'th May 2026
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
02:53pm, Monday, 04'th May 2026
Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects furt
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
12:15pm, Friday, 01'st May 2026
Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
10:52am, Friday, 01'st May 2026
Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for pati
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
05:31am, Friday, 01'st May 2026
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
09:45pm, Thursday, 30'th Apr 2026
Corcept Therapeutics (CORT) came out with a quarterly loss of $0.3 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
04:05pm, Thursday, 30'th Apr 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
04:05pm, Thursday, 30'th Apr 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)
02:31am, Friday, 24'th Apr 2026
Corcept Therapeutics (NASDAQ: CORT - Get Free Report) and Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two bu
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Thursday, 23'rd Apr 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026.
NEW YORK, April 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October
